CA
NZ
UK
AU
IND
US
…
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025 Aibotics Inc. is based in Miami, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aibotics Inc. is a publicly listed company on the OTC Pink market for which there are very limited reliable public disclosures describing its operations, product lines, or target markets. Because its business model and long-term growth drivers are not clearly documented, investors have little verifiable basis to assess revenue potential or competitive position. Some investors may be attracted by the potential upside typical of small, thinly traded microcap stocks, but that opportunity is speculative given the information gaps.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.22M | -1.85M | -1.18M | -2.61M | -5.14M |
| Net income | -2.22M | -1.85M | -1.18M | -2.61M | -5.14M |
| Selling general administrative | 1.85M | 1.63M | 0.62M | 1.88M | 2.67M |
| Selling and marketing expenses | - | - | 0.06M | - | - |
| Gross profit | 0.00M | -0.67M | -0.06M | -0.00M | -0.00M |
| Reconciled depreciation | 0.67M | 0.67M | 0.06M | 0.00M | 0.00M |
| Ebit | -1.84M | -2.30M | -0.62M | -1.74M | -4.99M |
| Ebitda | -1.18M | -1.63M | -0.56M | -1.74M | -4.99M |
| Depreciation and amortization | 0.67M | 0.67M | 0.06M | 0.00M | 0.00M |
| Operating income | -1.84M | -1.63M | -0.62M | -1.74M | -4.99M |
| Other operating expenses | 1.85M | 1.63M | 0.62M | 1.74M | 4.99M |
| Interest expense | 0.23M | 0.21M | 0.56M | 0.88M | 0.15M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.23M | -0.21M | -0.56M | -0.87M | -0.15M |
| Income tax expense | - | - | 0.15M | 0.88M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.85M | 0.97M | 0.56M | 1.74M | 4.99M |
| Cost of revenue | 0.67M | 0.67M | 0.06M | 0.00M | 0.00M |
| Total other income expense net | -0.37M | -0.21M | -0.56M | -0.88M | -0.15M |
| Net income from continuing ops | -2.22M | -1.85M | -1.18M | -2.61M | -5.14M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.87M | 1.46M | 2.22M | 0.39M | 1.27M |
| Intangible assets | 0.60M | 1.27M | 1.94M | - | - |
| Other current assets | 0.01M | - | - | - | - |
| Total liab | 4.83M | 4.85M | 4.25M | 1.28M | 1.22M |
| Total stockholder equity | -3.96M | -3.39M | -2.03M | -0.89M | 0.05M |
| Other current liab | 3.02M | 3.30M | 3.07M | 0.40M | 0.35M |
| Common stock | 0.49M | 0.04M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.49M | 0.04M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -13.03M | -10.81M | -8.96M | -7.78M | -5.17M |
| Cash | 0.26M | 0.19M | 0.28M | 0.39M | 1.27M |
| Total current liabilities | 4.83M | 4.85M | 4.25M | 0.76M | 0.59M |
| Current deferred revenue | - | - | - | -0.76M | - |
| Net debt | 1.03M | 1.08M | 0.81M | 0.27M | -0.52M |
| Short term debt | 1.28M | 1.26M | 1.09M | 0.14M | 0.12M |
| Short long term debt | 1.28M | 1.26M | 1.09M | 0.14M | 0.12M |
| Short long term debt total | 1.28M | 1.26M | 1.09M | 0.66M | 0.75M |
| Other stockholder equity | 8.58M | 7.37M | 6.92M | 6.87M | 5.21M |
| Total current assets | 0.27M | 0.19M | 0.28M | 0.39M | 1.27M |
| Long term debt | - | - | - | 0.51M | 0.62M |
| Accounts payable | 0.53M | 0.28M | 0.09M | 0.23M | 0.12M |
| Non currrent assets other | - | - | 0.00M | 0.00M | - |
| Non current assets total | 0.60M | 1.27M | 1.94M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | 0.00M | -0.00M |
| Total cashflows from investing activities | - | - | -0.00M | - | -0.00M |
| Net borrowings | 0.25M | 0.17M | 0.00M | -0.38M | 1.40M |
| Total cash from financing activities | 0.53M | 0.17M | 1.40M | -0.23M | 1.40M |
| Net income | -2.22M | -1.85M | -1.18M | -2.61M | -2.82M |
| Change in cash | 0.07M | -0.09M | -0.11M | -0.88M | 1.16M |
| Begin period cash flow | 0.19M | 0.28M | 0.39M | 1.27M | 0.11M |
| End period cash flow | 0.26M | 0.19M | 0.28M | 0.39M | 1.27M |
| Total cash from operating activities | -0.46M | -0.26M | -0.11M | -0.66M | -0.24M |
| Issuance of capital stock | 0.28M | - | 0.00M | 0.15M | 0.00M |
| Depreciation | 0.67M | 0.67M | 0.06M | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.53M | - | - | 0.15M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.93M | 0.83M | 0.58M | 0.17M | 0.47M |
| Stock based compensation | - | 0.00M | 0.00M | 1.02M | 4.31M |
| Other non cash items | 0.16M | 0.09M | 0.44M | 0.76M | 2.12M |
| Free cash flow | -0.46M | -0.26M | -0.11M | -0.66M | -0.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AIBT Aibotics Inc. |
-0.00 6.98% |
0.00 | - | - | 234.05 | 11.76 | 717.65 | -3.03 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025 Aibotics Inc. is based in Miami, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Benjamin Kaplan | Chairman, Chief Executive and Financial Officer & President | 1967 |
| Dr. Saphire Longmore MBBS | Chief Medical Officer Of Caribbean Affairs | NA |
| Mr. Benjamin Kaplan | Chairman, Chief Executive and Financial Officer & President | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...